4//SEC Filing
BELLICUM PHARMACEUTICALS, INC 4
Accession 0001358403-16-000300
CIK 0001358403operating
Filed
Dec 4, 7:00 PM ET
Accepted
Dec 5, 4:09 PM ET
Size
7.2 KB
Accession
0001358403-16-000300
Insider Transaction Report
Form 4
Spencer David M.
Chief Scientific Officer
Transactions
- Sale
Common Stock
2016-12-01$17.17/sh−2,967$50,942→ 153,115 total - Sale
Common Stock
2016-12-01$18.04/sh−2,033$36,682→ 151,082 total
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 21, 2016 by the Reporting Person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.74 to $17.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.78 to $18.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.Select
Documents
Issuer
BELLICUM PHARMACEUTICALS, INC
CIK 0001358403
Entity typeoperating
Related Parties
1- filerCIK 0001358403
Filing Metadata
- Form type
- 4
- Filed
- Dec 4, 7:00 PM ET
- Accepted
- Dec 5, 4:09 PM ET
- Size
- 7.2 KB